Virtual structure-based docking and molecular dynamics of fda-approved drugs for the identification of potential ikkb inhibitors possessing dopaminergic activity in alzheimer’s disease

HIGHLIGHTS

• who: Prasada Chowdari Gurram from the (UNIVERSITY) have published the research work: Virtual structure-based docking and molecular dynamics of FDA-approved drugs for the identification of potential IKKB inhibitors possessing dopaminergic activity in Alzheimeru2019s disease, in the Journal: (JOURNAL)
• what: Through this study the authors attempted to understand via in silico evaluation, the molecular docking attributes of IKKB with Zinc 15 FDA-approved compounds to identify molecules with potential IKKB inhibitory activity, which are previously known to activate the dopaminergic system, in the efforts of developing better treatment strategies towards managing AD. The analysis . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.